Bedrocan Expands UK Distribution Network

Dutch pharmaceutical cannabis producer Bedrocan has announced a major expansion of its UK distribution network, forming new supply partnerships with three established specialist pharmacy groups operating across England, Scotland and Wales.

Bedrocan products — cultivated under strict GMP certification in the Netherlands — are known for their pharmaceutical-grade consistency and standardised cannabinoid profiles. The expanded UK network will reduce fulfilment times and make the producer's full range of flower and oil preparations more accessible to patients nationwide.

What Does This Mean for Patients?

Previously, Bedrocan products were only available through a limited number of dispensing pharmacies concentrated in major urban centres. The new distribution agreements will extend coverage to regional and suburban areas, addressing a longstanding gap in patient access particularly felt outside London and the South East.

The company confirmed that all products distributed under the expanded network will carry consistent batch documentation, enabling prescribers and patients to track cannabinoid content and origin with full transparency — a key requirement under UK MHRA regulations.

Industry Context

The move comes amid growing competition in the UK medical cannabis supply market, with several international producers scaling their British operations. Bedrocan's expansion is expected to apply downward pressure on product pricing, which remains a significant barrier for many patients who fund prescriptions privately.

Advocates have welcomed the announcement, noting that improved supply chain infrastructure is essential for the long-term sustainability of the UK medical cannabis sector and for building confidence among prescribers who have been hesitant to adopt cannabis therapies due to inconsistent product availability.